

Cite this: *Mater. Adv.*, 2023,  
4, 195

# Surface engineered Fe<sub>3</sub>O<sub>4</sub> nanomagnets for pH-responsive delivery of gemcitabine hydrochloride and *in vivo* tracking by radiolabeling†

Bijaideep Dutta,<sup>ab</sup> Sandeep B. Shelar,<sup>a</sup> K. C. Barick,<sup>id</sup>\*<sup>ab</sup> Priyalata Shetty,<sup>c</sup>  
Rubel Chakravarty,<sup>bc</sup> Sudipta Chakraborty,<sup>bc</sup> Swati Checker,<sup>ad</sup> H. D. Sarma<sup>e</sup> and  
P. A. Hassan<sup>id</sup>\*<sup>ab</sup>

Gemcitabine, a well-known nucleoside analogue, has shown tremendous potential against solid tumors. However, its clinical use is limited due to its poor biological half-life and low target to non-target ratio. In this regard, we have developed polyphosphate grafted Fe<sub>3</sub>O<sub>4</sub> nanomagnets (PPNMs) for efficient delivery of gemcitabine hydrochloride (GEM). These nanocarriers are highly dispersible in physiological medium and possess sufficient surface charge (−25 mV) for electrostatic binding of positively charged GEM. The successful loading of GEM on PPNMs was evident from UV-visible absorption, FTIR spectroscopy and light scattering studies. The GEM loaded PPNMs (GEM-PPNMs) exhibited pH triggered release of the loaded drug, substantial cellular internalization, and higher toxicity towards human lung cancer (A549) and breast cancer (MCF-7) cell lines over pure drug. Further, the biodistribution of these nanocarriers was assessed by their tracking in a mouse model through radiolabeling with <sup>64</sup>Cu and <sup>177</sup>Lu. It has been observed that a radiolabeling yield of >90% can be achieved with PPNMs concentrations of 1 mg mL<sup>−1</sup> and 0.5 mg mL<sup>−1</sup> in 60 min for <sup>64</sup>Cu and <sup>177</sup>Lu, respectively, at room temperature. The radiolabeled PPNMs (<sup>64</sup>Cu-PPNMs and <sup>177</sup>Lu-PPNMs) were highly stable during the study period in saline solution. Though the radiolabeled system exhibited higher uptake in the liver and spleen upon intravenous injection, a substantial uptake of the same was also found in the tumor. Specifically, the present study demonstrated the efficacy of PPNMs for delivery of GEM as well as their *in vivo* tracking by radiolabeling.

Received 6th June 2022,  
Accepted 6th October 2022

DOI: 10.1039/d2ma00647b

rsc.li/materials-advances

## Introduction

The advancement of innovative materials for further improvement of their existing biological applications is the main focus

of researchers now-a-days worldwide. The design of nanomaterials with certain specific functional properties to achieve desired diagnostic and therapeutic efficacy is of prime importance.<sup>1,2</sup> This will refine the prevailing treatment procedure and help in eradicating the disease with ease. Starting from metal nanoparticles, metal oxide nanoparticles to metal and metal oxide hybrid nanoparticles are the choice of the decade for their simplicity in preparation and multifaceted applications. These nanoparticles provide a large surface area to play with and alter their overall activity as required time to time. Amid all this, Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles (MNPs) are typically significant for their exquisite magnetic properties which can change the course of the contemporary biomedical field. Because of their inimitable physicochemical properties and high biocompatibility nature, they can be used at cellular as well as subcellular level for numerous biological applications. Fe<sub>3</sub>O<sub>4</sub> MNPs have been assessed for various biomedical applications such as cargo carriers for bioactive molecules (drugs, genes), next generation contrast agents for magnetic resonance imaging and localized heat mediated cancer cell

<sup>a</sup> Chemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India. E-mail: kbarick@barc.gov.in, hassan@barc.gov.in; Fax: +91 22 2550 5151; Tel: +91 22 2559 0284

<sup>b</sup> Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India

<sup>c</sup> Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India

<sup>d</sup> PGDM (Pharmaceuticals & Biotechnology), SIES SBS, Nerul, Navi Mumbai 400706, India

<sup>e</sup> Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India

† Electronic supplementary information (ESI) available: Materials, synthesis and structural characterization, drug loading and release studies, cytotoxicity, cellular uptake and cell death studies, zeta-potential, time dependent variations of hydrodynamic diameter, UV-visible absorption spectra, cell viability, Prussian blue staining, pseudo first order kinetic model fitting and percentage of radioactivity leached plots, and protein–particle interaction data (Fig. S1–S7 and Table S1). See DOI: <https://doi.org/10.1039/d2ma00647b>



killing *via* application of an external AC magnetic field.<sup>3–7</sup> Of all uses, MNPs are exhaustively used as carriers for delivery of different chemotherapeutic drugs *via* active and passive targeting routes.<sup>8–10</sup>

Amongst chemotherapeutic agents, gemcitabine (2',2'-difluorodeoxycytidine), a nucleoside analogue, has been used against a variety of human tumors.<sup>11</sup> It is a cytostatic drug which acts as an antimetabolite by inhibiting DNA replication. But the drawback of gemcitabine therapy lies in its rapid degradation which leads to low circulation time and the need for higher dosage. The use of higher dosage to achieve effective therapeutic efficacy leads to undesired side effects.<sup>12</sup> Further, gemcitabine has poor cell membrane permeability, and thus, it generally internalizes into the cells *via* nucleoside transporters due to its hydrophilic characteristics.<sup>13</sup> Therefore, the expression of higher levels of nucleoside transporters is required in patients to achieve a substantial survival rate, which restricts its use in patients having lower levels of nucleoside transporters. There are very few studies reported in the literature on the delivery of gemcitabine using MNPs as a carrier, which could enhance its retention time and reduce its side effects.<sup>14–16</sup> Even though the use of MNPs as a drug carrier has many advantages, there are still some bottlenecks in their *in vivo* characteristics. Their efficacy was challenged many times due to recognition by our immune systems, mainly by the mononuclear phagocytic system (MPS) and reticuloendothelial system (RES) followed by clearance from the bloodstream as well as due to the presence of the blood–brain barrier. Thus, a strong competition exists between the distribution of MNPs in specific organs/tissues and their clearance mechanisms. The physicochemical property of MNPs affects the ultimate fate of the carriers upon administration *in vivo*.<sup>17</sup> In order to increase the *in vivo* plasma half-life, different stealth coatings are used on the carriers.<sup>18,19</sup> Therefore, the addition of a suitable surface passivating agent defines the mode of action of Fe<sub>3</sub>O<sub>4</sub> MNPs. Further, most of the studies are concerned with only *in vitro* level toxicity and cellular internalization. In order to achieve the actual potential of the nanocarrier, *in vivo* biodistribution studies are essential. Therefore, the tracking of Fe<sub>3</sub>O<sub>4</sub> MNPs movement in an animal model has paramount importance in their biomedical applications. Especially, the labelling of MNPs with suitable radionuclides is an advanced technique for biodistribution studies as well as their *in vivo* tracking using various multimodal imaging techniques.<sup>20,21</sup>

Herein, we have prepared negatively charged polyphosphate grafted Fe<sub>3</sub>O<sub>4</sub> nanomagnets (PPNMs), and explored their efficacy for intracellular delivery of the anticancer drug, gemcitabine hydrochloride (GEM) through electrostatic interactions. These nanocarriers are highly dispersible in physiological medium, and GEM loaded PPNMs (GEM-PPNMs) exhibited pH dependent drug release characteristics, substantial cellular uptake and higher toxicity to human lung cancer (A549) and breast cancer (MCF-7) cell lines. Further, the biological activity of these nanocarriers was assessed by their tracking in a mouse model through radiolabeling with <sup>64</sup>Cu and <sup>177</sup>Lu. It is noteworthy to mention that the radiolabeled PPNMs were stable

during the study period and substantial uptake of the same was also found in the tumor.

## Experimental

### Synthesis, structural characterization, drug interaction and cellular studies of PPNMs

PPNMs were synthesized through co-precipitation of ferrous and ferric ions (1 : 2 molar ratio) in the presence of ammonium hydroxide (25%) followed by the introduction of sodium tripolyphosphate (STTP) as a surface passivating agent.<sup>22</sup> The structural characterization (phase identification, determination of shape, size and surface properties) and magnetic properties of PPNMs were studied by X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), dynamic light scattering (DLS), zetasizer and physical property measurement system, *etc.*

The interaction of GEM with PPNMs was explored by monitoring the changes in surface charge and absorbance. The drug loading efficiency was determined from UV-visible absorption spectroscopic studies at pH 4, 6 and 8 with different drug to particle ratios. The pH mediated release of the drug from GEM-PPNMs was achieved under reservoir (r)-sink (s) conditions at 37 °C. The cytotoxicity of GEM and GEM-PPNMs was examined against MCF-7 cells at five different concentrations of the drug ranging from 0.001 to 10 μM. The details of synthesis, structural characterization, drug loading and release, cytotoxicity, cellular uptake and cell death studies are provided in the ESI.†

### Production of radionuclides (<sup>64</sup>Cu and <sup>177</sup>Lu) and radiolabeling of PPNMs

<sup>64</sup>Cu was produced *via* <sup>64</sup>Zn(n,p)<sup>64</sup>Cu by irradiation of the isotopically enriched (99.4% in <sup>64</sup>Zn) ZnO target. No-carrier added <sup>64</sup>Cu was extracted from the irradiated target in the form of [<sup>64</sup>Cu]CuCl<sub>2</sub> solution in 0.01 M HCl following the procedure reported elsewhere.<sup>23</sup> <sup>177</sup>Lu was produced *via* the <sup>176</sup>Lu(n,γ)<sup>177</sup>Lu route by direct neutron bombardment of the isotopically enriched (74.5% in <sup>176</sup>Lu) Lu<sub>2</sub>O<sub>3</sub> target. The irradiated target was converted to [<sup>177</sup>Lu]LuCl<sub>3</sub> solution in 0.01 M HCl as per the reported procedure.<sup>24</sup>

Radiolabeling of PPNMs with <sup>64</sup>Cu and <sup>177</sup>Lu was performed using [<sup>64</sup>Cu]CuCl<sub>2</sub> and [<sup>177</sup>Lu]LuCl<sub>3</sub> radiochemical precursors, respectively. Briefly, 0.1 mL solution of [<sup>64</sup>Cu]CuCl<sub>2</sub> (4 MBq of <sup>64</sup>Cu) or [<sup>177</sup>Lu]LuCl<sub>3</sub> (20 MBq of <sup>177</sup>Lu) (both in 0.01 mL of HCl) was first added to the aqueous dispersion of PPNMs (0.2, 0.5, 1.0 and 2.0 mg in 1.0 mL of Milli Q water). The pH of the mixture was adjusted to ~5.5 by addition of a few drops of 0.1 M NaHCO<sub>3</sub> solution. The total volume of the mixture was maintained at 2.0 mL using Milli Q water and the mixture was kept at room temperature under continuous stirring for adsorption of radionuclides onto the surface of PPNMs. Subsequently, the suspended radiolabeled PPNMs were magnetically separated by using a table-top magnet. For determination of percentage of radiolabeling, an aliquot (typically, 100 μL) of the clear supernatant was carefully withdrawn and its radioactivity



was measured. The radioactivity of the same volume of 'blank' was also measured. The 'blank' solution was prepared by diluting 0.1 mL of [ $^{64}\text{Cu}$ ]CuCl<sub>2</sub> (4 MBq of  $^{64}\text{Cu}$ ) or [ $^{177}\text{Lu}$ ]LuCl<sub>3</sub> (20 MBq of  $^{177}\text{Lu}$ ) with 1.9 mL of Milli Q water, where no PPNMs were added. The percentage of radiolabeling yield was calculated using the following equation:

$$\% \text{ Radiolabeling yield} = \left(1 - \frac{R}{B}\right) \times 100$$

where 'B' and 'R' represent the background-corrected radioactivity of 'blank' and supernatant solution of the reaction mixture, respectively. The percentage of radiolabeling yield was determined for both  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labeling as a function of concentration of PPNMs and time of incubation.

### *In vitro* stability of radiolabeled PPNMs

The *in vitro* stability of  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labeled PPNMs was investigated in normal saline and rat serum. *In vitro* stability in normal saline was explored by diluting 0.2 mL of [ $^{64}\text{Cu}$ ]Cu-PPNMs and [ $^{177}\text{Lu}$ ]Lu-PPNMs formulations with 1.8 mL of normal saline. The mixtures were kept at 37 °C for up to 2 days for the  $^{64}\text{Cu}$ -labeled formulation and for 15 days for the  $^{177}\text{Lu}$ -labeled formulation. The percentage of  $^{64}\text{Cu}$  or  $^{177}\text{Lu}$  activity leached out into the saline from radiolabeled formulations at different time intervals post-preparation was determined following the same procedure used for determination of radiolabeling yields. From this, the percentage radioactivity that remained associated with PPNMs as a function of time post-preparation was determined, which ascertains the *in vitro* stability of the formulations in saline.

*In vitro* stability in rat serum was studied by thoroughly mixing 0.2 mL of formulations with 1.8 mL of freshly isolated rat serum. The mixtures were kept at 37 °C for up to 2 days. The percentage radioactivity that remained associated with PPNMs as a function of time post-preparation was determined as in the previous case.

### *In vivo* biodistribution studies of radiolabeled PPNMs

Biodistribution studies of the radiolabeled PPNMs formulations were performed in C57BL/6 mice bearing melanoma tumor as per the protocol approved by the Institutional Animal Ethics Committee of the Bhabha Atomic Research Centre, Mumbai, India.

Melanoma tumors were developed by injecting about  $1 \times 10^6$  melanoma cells suspended in 200  $\mu\text{L}$  of PBS to the right thigh of C57BL/6 mice (weight: 20–25 g). The animals were monitored for development of tumors and the biodistribution studies were carried out once the tumor volume reached 150–200 mm<sup>3</sup> (~2 weeks after inoculation). An aliquot (0.1 mL) of the radiolabeled formulation (2–3 MBq) was injected intravenously into each tumor-bearing mouse. In the case of mice injected with  $^{64}\text{Cu}$ -PPNMs, a group of 4 mice were sacrificed by CO<sub>2</sub> asphyxiation at 1, 4 and 24 h post injection (p.i.). Various organs/tissues were collected by thoroughly washing with saline (except blood) and dried. The radioactivity associated with them was determined using a flat-type NaI (Tl) scintillation




Fig. 1 (a) XRD pattern, (b) FTIR spectrum, (c) TEM image and (d) magnetization plot of PPNMs. The FTIR spectra of STTP and bare MNPs are included in part (b) for comparative purpose. Bare MNPs ( $\text{Fe}_3\text{O}_4$  nanoparticles without functionalization of STTP) were prepared by a similar method without using STTP during synthesis.

counter. The percentage of injected radioactivity dose (% ID) in various organs/tissues was determined and provided as percentage injected radioactivity dose per gram (% ID g<sup>-1</sup>) of organ/tissue. In the case of  $^{177}\text{Lu}$ -PPNMs, biodistribution studies were performed at 1, 4, 24, 72 and 168 h p.i.

## Results and discussion

The primary objective of the present study was exploration of the capability of negatively charged  $\text{Fe}_3\text{O}_4$  nanomagnets for delivery of GEM and investigation of their *in vivo* biodistribution by radiolabeling. STTP was employed as a surface passivating agent due to its biocompatible nature and higher binding affinity towards  $\text{Fe}_3\text{O}_4$  via bidentate and tridentate bridging geometry. PPNMs were prepared as reported earlier by our group and well-characterized by XRD, TEM, FTIR, TGA and magnetic measurements.<sup>22</sup> Here, the typical XRD pattern, FTIR spectrum, TEM image and magnetization plot of PPNMs are provided (Fig. 1) to confirm their successful phase formation and organic modifications. Briefly, the appearance of sharp and intense characteristic diffraction peaks corresponding to (220), (311), (400), (422), (511) and (440) planes in the XRD pattern of PPNMs (Fig. 1a) confirmed the formation of the highly crystalline single phase  $\text{Fe}_3\text{O}_4$  nanostructure (JCPDS Card No. 88-0315). The characteristic stretching vibrational bands associated to P=O, PO<sub>2</sub> and PO<sub>3</sub> groups, and the P-O-P bridge are found in the FTIR spectrum of pure STTP (Fig. 1b).<sup>22</sup> These modes are observed in the FTIR spectrum of PPNMs with a slight shift in their band position in the range of 700–1250 cm<sup>-1</sup>, whereas they are absent in bare MNPs. Further, the






Fig. 2 (a) DLS and (b) zeta-potential plots of PPNMs in physiological medium. The inset of part (b) shows the photograph of colloidal dispersion of PPNMs in physiological medium.

intense band at  $\sim 575\text{ cm}^{-1}$  in PPNMs can be ascribed to the Fe–O stretching vibration of  $\text{Fe}_3\text{O}_4$ . The TEM image of PPNMs (Fig. 1c) reveals the formation of mostly spherical particles of size  $\sim 10\text{ nm}$  and they show superparamagnetic behavior without hysteresis and remanence at 300 K. The maximum magnetization of PPNMs was found to be  $51\text{ emu g}^{-1}$  at 15 kOe.


Colloidal stability of nanoparticles in physiological medium (PBS) is essential for their biological applications. Fig. 2 presents (a) DLS and (b) zeta-potential plots of PPNMs in physiological medium. The DLS plot (Fig. 2a) shows that PPNMs are highly dispersible in physiological medium (PBS, pH 7.4) and possess a mean intensity weighted hydrodynamic diameter of about 170 nm with a polydispersity index (PDI) of 0.25. The corresponding number weighted hydrodynamic diameter was found to be around 50 nm by using the DLS software. The zeta-potential analysis revealed that the surface charge of PPNMs in

Table 1 Loading efficiency of GEM obtained by varying the ratio of drug to particles as well as pH of the reaction medium

pH of the reaction medium	Amount of GEM ( $\mu\text{g}$ )	Amount of PPNMs ( $\mu\text{g}$ )	Drug to particle ratio	Loading efficiency (%)
6	10	50	1 : 5	2.3
	10	100	1 : 10	5.6
	10	200	1 : 20	10.5
	10	400	1 : 40	23.7
	10	800	1 : 80	21.6
4	10	400	1 : 40	19.0
6	10	400	1 : 40	23.7
8	10	400	1 : 40	21.9

physiological medium was about  $-25\text{ mV}$  (Fig. 2b), whereas that of bare MNPs was  $-15\text{ mV}$  (Fig. S1, ESI<sup>†</sup>). The appearance of such a high negative surface charge on PPNPs is mainly due to the occurrence of phosphate moieties on their exterior, which is adequate for electrostatic stabilization of particles. Further, the hydrogen bonds between oxygen molecules of phosphate moieties and water provide additional colloidal stability to PPNMs. The good colloidal stability of PPNMs is also evident from the photograph of dispersion of PPNMs in physiological medium (inset of Fig. 2b) and the insignificant change in their hydrodynamic diameter in physiological medium with respect to time (Fig. S2, ESI<sup>†</sup>). Moreover, they should have lesser binding affinity towards macrophages, plasma proteins or other cell membranes being negatively charged.

These negatively charged PPNMs were used for electrostatic conjugation of positively charged GEM (due to the protonation of the  $\text{NH}_2$  group) as shown in Scheme 1. The loading efficiency of GEM was augmented by changing the ratio of drug to particles as well as pH of the medium, as shown in Table 1. A maximum loading efficiency of 23.7% was found at a drug to particle ratio of 1:40 at pH 6 from UV-visible absorption studies. Parsian *et al.* found a maximum loading efficiency of about 39% by interacting chitosan coated MNPs ( $2.5\text{ mg mL}^{-1}$ ) with  $22.5\text{ }\mu\text{g mL}^{-1}$  of GEM.<sup>25</sup> Even though the maximum loading efficiency is quite low in the present study, the GEM loaded PPNMs exhibited higher cytotoxicity over pure GEM (discussed later). A typical UV-visible absorption spectrum of the supernatant solution (obtained after magnetic removal of GEM-PPNMs) along with standard curves are shown in Fig. S3



Scheme 1 Pictorial representation of conjugation of GEM onto the surface of PPNMs.








Fig. 3 (a) FTIR spectra of pure GEM, PPNMs and GEM-PPNMs and (b) DLS plot of GEM-PPNMs showing the intensity weighted hydrodynamic diameter.

(ESI<sup>†</sup>). The surface charge of GEM-PPNMs in aqueous medium was  $-5$  mV at pH 6, whereas that of PPNMs was  $-28$  mV. This significant increase in surface charge from  $-28$  mV to  $-5$  mV could be described by neutralization of the negative charge through loading of GEM.<sup>14</sup> The loading of GEM on PPNMs was further supported from FTIR and DLS analysis. Fig. 3 shows (a) the FTIR spectra of pure GEM and GEM-PPNMs and (b) the DLS plot of GEM-PPNMs showing the intensity weighted hydrodynamic diameter. The peak at  $577\text{ cm}^{-1}$  in the FTIR spectrum of GEM-PPNMs can be ascribed to the Fe-O stretching vibrational mode of  $\text{Fe}_3\text{O}_4$ .<sup>22</sup> The FTIR spectrum of GEM showed bands at approximately  $1645$  and  $1065\text{ cm}^{-1}$  due to the bending modes of  $-\text{NH}/\text{OH}$  and stretching vibration of C-O, respectively.<sup>26,27</sup> The broad band that appeared in the  $3000\text{--}3700\text{ cm}^{-1}$  region




Fig. 4 pH dependent release profile of the drug from GEM-PPNMs under reservoir sink conditions at  $37\text{ }^\circ\text{C}$  (the inset shows the linear relationship between drug release and square root of time). The standard deviation shown in the plot was determined by performing each experiment in triplicate.

can be ascribed to  $-\text{NH}/\text{OH}$  stretching vibrational modes.<sup>27</sup> Interestingly, these characteristic bands of GEM are also observed in the FTIR spectrum of GEM-PPNMs suggesting the loading of the drug onto the surface of PPNMs (absent in the FTIR spectrum of PPNMs). In addition, the increase in mean intensity weighted hydrodynamic diameter from  $170$  to  $195$  nm upon conjugation of GEM onto the surface of PPNMs further supports the successful loading of the drug. Moreover, the interaction of GEM-PPNMs with protein was explored utilizing BSA as a model protein and the observed results are shown in Table S1 (ESI<sup>†</sup>). The insignificant change in the surface charge of GEM-PPNMs in BSA solution suggested their good resistance towards protein interaction. The maximum drug loaded PPNMs sample was used for further studies.

Fig. 4 shows the pH responsive release of the drug from GEM-PPNMs under reservoir sink conditions at  $37\text{ }^\circ\text{C}$ . The drug release study was performed in a mild acidic medium as the pH of subcellular organelles like lysosomes and endosomes (late stage) is in the range of pH 3–5.<sup>28</sup> It was found that the loaded GEM was released in a pH dependent manner with higher release at lower pH. The amount of drug release over a period of 50 h was found to be 15, 45 and 80% at pH 7.4, 5 and 4, respectively. The short time release characteristic shows a linear relationship between GEM release and square root of time ( $t^{1/2}$ ) as anticipated from the Higuchi drug release model (inset of Fig. 4). This indicates that the release of GEM from nanocarriers occurs in a diffusion-controlled manner.<sup>29</sup> It is worth mentioning that in a mild acidic medium (pH 5) the protonation of the phosphate group leads to a decrease in the electrostatic interaction between drug molecules and nanocarriers, thereby enhancing the release of the drug from the carrier. This was not observed in physiological medium (pH 7.4). At a still lower pH of 4, the drug release percentage was






Fig. 5 Viability of A549 and MCF-7 cells incubated in the medium containing GEM and GEM-PPNMs for (a) 24 h and (b) 48 h. Mean values were expressed as mean  $\pm$  SEM for  $n = 3$  in each experimental group. Statistical significance between GEM and GEM-PPNMs treatment groups was calculated using the Student's *t*-test, where \* indicates  $p < 0.05$ .

found to be further increased. Similar pH-responsive release of the drug from GEM loaded nanocarriers was observed by various research groups.<sup>25,30–32</sup> For instance, Parsian *et al.* reported only 8% release of GEM from chitosan coated MNPs at pH 7.2, whereas the release was 65.4% at pH 4.2.<sup>25</sup> Mottaghtalab *et al.* observed a faster release rate of GEM at pH 5 in comparison to pH 7.4 from the GEM loaded silk fibroin nanoparticles.<sup>30</sup> The observed pH mediated slow and sustained drug release profile in the present study suggested that the developed carriers can be utilized for intracellular delivery of GEM. Further, the quite slow release of GEM from the developed nanocarriers at pH 7.4 is highly beneficial for its stability

in blood as the half-life of free GEM is very short (8–17 min) under physiological conditions.<sup>33</sup>

Fig. 5 shows the viability of A549 and MCF-7 cells incubated in the medium containing GEM and GEM-PPNMs for 24 h and 48 h. From MTT assay, it has been found that both GEM and GEM-PPNMs induced dose-dependent toxicity against both A549 and MCF-7 cells upon incubation for 24 h and 48 h. The cytotoxicity of GEM and GEM-PPNMs is more prominent with 48 h incubation in both the cell lines. It is noteworthy to mention that the developed formulation has higher toxicity over pure GEM (toxicity data of GEM-PPNMs are statistically significant against the respective GEM group,  $p < 0.05$ ), which is advantageous for therapeutic applications. The observed higher toxicity could be associated with the increase in cellular uptake of the drug by endocytosis of GEM-PPNMs.<sup>25,32</sup> In addition, the nanocarriers do not show toxicity to both A549 and MCF-7 cells up to a concentration of  $200 \mu\text{g mL}^{-1}$ , suggesting their safe *in vivo* use (Fig. S4, ESI†).

Different staining techniques are commonly used to visualize the cellular processes by optical or fluorescence imaging of cells.<sup>34–38</sup> The cellular uptake of PPNMs was confirmed from the Prussian blue staining study in MCF-7 cells. From the vivid blue-coloured deposition (due to the formation of ferric ferrocyanide) in MCF-7 cells incubated with PPNMs (Fig. S5, ESI†), it can be deduced that a substantial amount of particles are successfully internalized into the cells as compared to their little cell surface attachment.<sup>34</sup> Acridine orange/ethidium bromide (AO/EB) fluorescence staining was further performed with A549 and MCF-7 cells to understand the cell death process after treating with GEM and GEM-PPNMs at a drug concentration of  $2.5 \mu\text{M}$  for 48 h. Fig. 6 shows the fluorescent microscopic images of A549 and MCF-7 cells providing morphological evidence of apoptosis by AO/EB dual staining. The nuclei of





Fig. 6 Fluorescent microscopic images of A549 and MCF-7 cells showing morphological evidence of apoptosis by AO/EB dual staining. The control cells show intact morphology, whereas a few apoptotic cells are observed in cells treated with GEM and GEM-PPNMs along with apoptotic bodies and fragmented nuclei.





Scheme 2 Pictorial representation of radiolabeling of PPNMs with  $^{64}\text{Cu}^{2+}$  and  $^{177}\text{Lu}^{3+}$ .

cells having uniform chromatin with intact cell membranes (control or viable cells) are stained in green colour by AO, whereas those with loss of membrane integrity and with different stages of cell death are stained differently with EB. In general, the early apoptosis cells displayed a bright green region with yellowish green nuclear fragmentation, and membrane bubbles and apoptotic bodies outside, whereas the late apoptosis cells showed orange-yellow or red nuclei with condensed or fragmented chromatin.<sup>39</sup> The changes of colour from light orange to pale red in the present study suggested that most of the cells were dead *via* apoptosis mode due to the action of GEM and GEM-PPNMs on both the cancer cell lines. Thus, GEM-PPNMs may serve as a promising tool for intracellular delivery of drugs. Further, GEM resistance developed by some cancer cells due to the loss of certain human equilibrative nucleoside transporters (hENTs) can be overcome

through its carrier mediated delivery as hENTs are not required for cellular uptake of the drug.<sup>40</sup> Being magnetic in nature, these nanocarriers can also be used as an effective heating source for hyperthermia therapy as well as a contrast agent in magnetic resonance imaging.<sup>3,6</sup> Moreover, these nanocarriers possess good magnetic field responsivity, and therefore, they can be accumulated at the site of interest by applying an external magnetic field.<sup>25</sup>

Radiolabeling of  $\text{Fe}_3\text{O}_4$  MNPs is a common method for monitoring the distribution of the nanoparticles *in vivo*.<sup>20,21</sup> We have carried out radiolabeling of PPNMs with  $^{64}\text{Cu}^{2+}$  and  $^{177}\text{Lu}^{3+}$  (Scheme 2) by exploiting the high coordinative affinity of polyphosphate moieties of PPNMs towards metal ions as a driving force for radiolabeling. It is noteworthy to mention that these polyphosphate moieties capture  $^{64}\text{Cu}^{2+}$  and  $^{177}\text{Lu}^{3+}$  ions from solution by forming chelate complexes like those of carboxylate ions and metal ions.<sup>41</sup> The kinetics of radiolabeling with  $^{64}\text{Cu}$  and  $^{177}\text{Lu}$  using different concentrations of PPNMs is shown in Fig. 7(a) and (b), respectively. It has been observed that for  $^{64}\text{Cu}$ , a radiolabeling yield of  $>90\%$  can be achieved when a PPNMs concentration of  $1\text{ mg mL}^{-1}$  is used and the reactions are performed for 60 min at room temperature (Fig. 7a). On the other hand, the optimum condition for obtaining  $>90\%$  radiolabeling with  $^{177}\text{Lu}$  was found to be incubation of PPNMs at  $0.5\text{ mg mL}^{-1}$  concentration with  $^{177}\text{LuCl}_3$  for 60 min at room temperature (Fig. 7b). It has been found that the radiolabeling of PPNMs with  $^{64}\text{Cu}$  and  $^{177}\text{Lu}$  mostly follows a pseudo first order kinetic model. The typical plots showing radiolabeling of PPNMs with  $^{64}\text{Cu}$  and  $^{177}\text{Lu}$  (PPNMs concentration of  $1\text{ mg mL}^{-1}$ ) are provided in Fig. S6 (ESI<sup>†</sup>).

*In vitro* stability assessment of  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labeled formulations showed that both the formulations retained their radiochemical stability in normal saline and rat serum up to the time of study mentioned in the experimental section. In all the cases, the percentage of radioactivity leached out from the radiolabeled formulations at the end of investigations was less than 5% (Fig. S7, ESI<sup>†</sup>). These results indicate the robustness of binding of  $^{64}\text{Cu}$  and  $^{177}\text{Lu}$  radioisotopes with PPNMs, which results in appreciably high radiochemical stability of the radiolabeled nanoformulations under physiological conditions.

After intravenous injection of  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labeled PPNMs in C57BL/6 mice bearing melanoma tumor, *in vivo*




Fig. 7 Kinetics of radiolabeling of PPNMs with (a)  $^{64}\text{Cu}$  and (b)  $^{177}\text{Lu}$  using different concentrations of nanoparticles.








Fig. 8 Biodistribution patterns of (a)  $^{64}\text{Cu}$ -PPNMs and (b)  $^{177}\text{Lu}$ -PPNMs in C57BL/6 mice bearing melanoma tumor (a group of 4 mice were used for each time frame).

biodistribution studies were performed by sacrificing the mice at different time points. The biodistribution patterns of  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labeled PPNMs are shown in Fig. 8(a) and (b), respectively. It is observed that both  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -labelled PPNMs are primarily taken up by macrophages in different MPS organs, specifically liver and spleen, with immediate clearance from blood. The activity accumulated in the liver and spleen was found to decrease slowly with time. For example, the % ID  $\text{g}^{-1}$  decrease in the liver (from  $\sim 52.62\%$  at 1 h to  $30.08\%$  at 168 h) and spleen (from  $15.29\%$  to  $11.72\%$  at 168 h) in  $^{177}\text{Lu}$ -PPNMs treated mice indicates the clearance of PPNMs from the liver and spleen with time. However, a slower degradation rate was observed in spleen macrophages as compared to liver Kupffer cells possibly due to the presence of less iron storage proteins in spleen. The observed results match well with earlier reports on intravenously injected MNPs, which discussed their higher

uptake in the liver and spleen.<sup>42,43</sup> A small fraction of PPNMs was also observed in the lungs and GIT, which slowly cleared with time. The radioactivity in the kidney showed that a minor portion of the radiolabeled PPNMs was excreted *via* urine. It is noteworthy to mention that the tumor uptake of PPNMs increases with time and a maximum uptake having  $3.16\% \text{ ID } \text{g}^{-1}$  was observed in  $^{177}\text{Lu}$ -PPNMs treated mice at 24 h p.i., and this slowly decreased. Further, the retention of a substantial amount of radiolabeled PPNMs at the tumor site even at 168 h p.i. suggests their good potential as a nanocarrier for *in vivo* drug delivery. This is also required for radiotherapeutic usage. Moreover, the higher uptake of PPNMs in the liver can be useful for identifying liver cancer through MRI as higher uptake of PPNMs by Kupffer cells of the normal liver produces a dark contrast in  $T_2$ -weighted MRI, whereas the tumor sites lacking Kupffer cells and thereby phagocytized PPNMs appear as bright regions.<sup>44</sup>

The ratios of target to nontarget uptake of the radiolabeled PPNMs were calculated and the results are shown in Table 2. In the case of  $^{177}\text{Lu}$ -PPNMs, the tumor to blood ratio was found to increase from 0.78 at 1 h p.i. to 10.39 at 168 h p.i., and the tumor to liver ratio was found to increase from 0.04 to 0.08 during the same time period. The accretion of PPNMs at the tumor site can be further increased by conjugation of suitable targeting agents with PPNMs.<sup>45</sup> Specifically, the present study investigated the *in vivo* biodistribution of magnetic nanocarriers in a mouse model through radiolabeling and their efficacy for intracellular delivery of positively charged anticancer agents.

## Conclusion

Anticancer drug, GEM was successfully loaded onto the negatively charged PPNMs through electrostatic interactions. GEM loaded PPNMs showed pH dependent release characteristics and exhibited higher toxicity towards MCF-7 and A549 cell lines over the pure drug. Further, the biodistribution of these nanocarriers was investigated in a mouse model by radiolabeling. The polyphosphate moieties on PPNMs capture  $^{64}\text{Cu}^{2+}$  and  $^{177}\text{Lu}^{3+}$  ions from solution by forming chelate complexes and this radiolabeling process follows a pseudo first order kinetic model. From *in vivo* studies, a substantial amount of radiolabeled PPNMs was found in the tumor. Therefore, the developed PPNMs can be used for delivery of GEM as well as *in vivo* tracking by radiolabeling.

Table 2 Tumor/blood and tumor/liver ratio of  $^{64}\text{Cu}$ - and  $^{177}\text{Lu}$ -PPNMs at various time points post-administration in C57BL/6 mice bearing melanoma tumor

Time p.i.	1 (h)	4 (h)	24 (h)	72 (h)	168 (h)
$^{64}\text{Cu}$ -PPNMs					
Tumor/blood	$0.62 \pm 0.12$	$1.31 \pm 0.16$	$1.96 \pm 0.31$	—	—
Tumor/liver	$0.03 \pm 0.01$	$0.06 \pm 0.01$	$0.06 \pm 0.12$	—	—
$^{177}\text{Lu}$ -PPNMs					
Tumor/blood	$0.78 \pm 0.18$	$1.37 \pm 0.17$	$2.86 \pm 0.29$	$5.12 \pm 0.48$	$10.39 \pm 0.76$
Tumor/liver	$0.04 \pm 0.01$	$0.06 \pm 0.02$	$0.07 \pm 0.02$	$0.08 \pm 0.03$	$0.08 \pm 0.10$





## Author contributions

Bijaideep Dutta: investigation, methodology, data curation, and writing – original draft. Sandeep B. Shelar: investigation, methodology, and data curation. K. C. Barick: project administration, writing – review & editing, supervision, conceptualization, and visualization. Priyalata Shetty: investigation, methodology, and validation. Rubel Chakravarty: investigation, validation, formal analysis, and writing – review & editing. Sudipta Chakraborty: formal analysis, visualization, and writing – review & editing. Swati Checker: investigation, methodology, and data curation. H. D. Sarma: investigation, methodology, and data curation. P. A. Hassan: project administration, writing – review & editing, supervision, and resources.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors acknowledge Dr A. K. Tyagi, Director, Chemistry Group, and Dr S. Kannan, Director, Radiochemistry & Isotope Group, BARC for their constant support and encouragement. Thanks are due to Mr K. C. Jagadeesan and Dr S. V. Thakare, Radiopharmaceuticals Division, BARC for arranging irradiation of the targets in Dhruva and APSARA-U reactor facilities at BARC. The staff members of the Radiochemical Section, Radiopharmaceuticals Division, BARC are acknowledged for radiochemical processing of the irradiated targets. The authors are also thankful to IIT Bombay and TPD, BARC for TEM imaging and magnetic measurements, respectively.

## References

- 1 S. C. Baetke, T. Lammers and F. Kiessling, Applications of nanoparticles for diagnosis and therapy of cancer, *Br. J. Radiol.*, 2015, **88**, 1054.
- 2 Z. Wenlong, F. Gu, J. M. Chan and A. Wang, Nanoparticles in medicine: therapeutic applications and developments, *Clin. Pharm. Therap.*, 2008, **83**, 761–769.
- 3 K. C. Barick, S. Singh, N. V. Jadhav, D. Bahadur, B. N. Pandey and P. A. Hassan, pH-responsive peptide mimic shell cross-linked magnetic nanocarriers for combination therapy, *Adv. Funct. Mater.*, 2012, **22**, 4975–4984.
- 4 L. Wu, L. Zong, H. Ni, X. Liu, W. Wen, L. Feng, J. Cao, X. Qi, Y. Ge and S. Shen, Magnetic thermosensitive micelles with upper critical solution temperature for NIR triggered drug release, *Biomater. Sci.*, 2019, **7**, 2134–2143.
- 5 Q. Xu, T. Zhang, Q. Wang, X. Jiang, A. Li, Y. Li, T. Huang, F. Li, Y. Hu, D. Ling and J. Gao, Uniformly sized iron oxide nanoparticles for efficient gene delivery to mesenchymal stem cells, *Int. J. Pharm.*, 2018, **552**, 443–452.
- 6 B. Dutta, A. Nema, N. G. Shetake, J. Gupta, K. C. Barick, M. A. Lawande, B. N. Pandey, I. K. Priyadarsini and P. A. Hassan, Glutamic acid-coated Fe<sub>3</sub>O<sub>4</sub> nanoparticles for tumor-targeted imaging and therapeutics, *Mater. Sci. Eng., C*, 2020, **112**, 110915.
- 7 M. Arruebo, R. Fernandez-Pacheco, M. Ricardo Ibarra and J. Santamaria, Magnetic nanoparticles for drug delivery, *Nanotoday*, 2007, **2**, 22–32.
- 8 B. Dutta, N. G. Shetake, B. K. Barick, K. C. Barick, B. N. Pandey, K. I. Priyadarsini and P. A. Hassan, pH sensitive surfactant-stabilized Fe<sub>3</sub>O<sub>4</sub> magnetic nanocarriers for dual drug delivery, *Colloids Surf., B*, 2018, **162**, 163–171.
- 9 T. Yang, D. Niu, J. Chen, J. He, S. Yang, X. Jia, J. Hao, W. Zhao and Y. Li, Biodegradable organosilica magnetic micelles for magnetically targeted MRI and GSH-triggered tumor chemotherapy, *Biomater. Sci.*, 2019, **7**, 2951–2960.
- 10 N. Saxena, H. Agrawal, K. C. Barick, D. Ray, V. K. Aswal, A. Singh, U. C. S. Yadav and C. L. Dube, Thermal and microwave synthesized SPIONs: Energy effects on the efficiency of nano drug carriers, *Mater. Sci. Eng., C*, 2020, **111**, 110792.
- 11 L. H. Reddy and P. Couvreur, Novel Approaches to Deliver Gemcitabine to Cancers, *Cur. Pharm. Des.*, 2008, **14**, 1124–1137.
- 12 C. A. Dasanu, Gemcitabine: vascular toxicity and prothrombotic potential, *Expert Opin. Drug Saf.*, 2008, **7**, 703–716.
- 13 F. Joubert, L. Martin, S. Perrier and G. Pasparakis, Development of a gemcitabine-polymer conjugate with prolonged cytotoxicity against a pancreatic cancer cell line, *ACS Macro Lett.*, 2017, **6**, 535–540.
- 14 M. Parsian, G. Unsoy, P. Mutlu, S. Yalcin, A. Tezcaner and U. Gunduz, Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug, *Eur. J. Pharm.*, 2016, **784**, 121–128.
- 15 J. L. Viota, A. Carazo, J. A. Munoz-Gamez, K. Rudzka, R. Gómez-Sotomayor, A. Ruiz-Extremera, J. Salmerón and A. V. Delgado, Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation, *Mater. Sci. Eng., C*, 2013, **33**, 1183–1192.
- 16 G. García-García, F. Fernández-Álvarez, L. Cabeza, Á. V. Delgado, C. Melguizo, J. C. Prados and J. L. Arias, Gemcitabine-loaded magnetically responsive poly( $\epsilon$ -caprolactone) nanoparticles against breast cancer, *Polymers*, 2020, **12**, 2790.
- 17 A. A. Belanova, N. Gavalas, Y. M. Makarenko, M. M. Belousova, A. V. Soldatov and P. V. Zolotukhin, Physicochemical properties of magnetic nanoparticles: Implications for biomedical applications in vitro and in vivo, *Oncol. Res. Treat.*, 2018, **41**, 139–143.
- 18 H. Arami, A. Khandhar, D. Liggitt and K. M. Krishnan, In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles, *Chem. Soc. Rev.*, 2015, **44**, 8576–8607.
- 19 J. S. Suk, Q. Xu, N. Kim, J. Hanes and L. M. Ensign, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, *Adv. Drug Deliv. Rev.*, 2016, **99**, 28–51.
- 20 M. Mirković, M. Radović, D. Stanković, Z. Milanović, D. Janković, M. Matović, M. Jeremić, B. Antić and S. Vranješ-Durić,



- <sup>99m</sup>Tc-bisphosphonate-coated magnetic nanoparticles as potential theranostic nanoagent, *Mater. Sci. Eng., C*, 2019, **102**, 124–133.
- 21 M. B. Schütz, A. M. Renner, S. Ilyas, K. Lê, M. Guliyev, P. Krapf, B. Neumaier and S. Mathur, <sup>18</sup>F-Labeled magnetic nanovectors for bimodal cellular imaging, *Biomater. Sci.*, 2021, **9**, 4717–4727.
- 22 J. Majeed, K. C. Barick, N. G. Shetake, B. N. Pandey, P. A. Hassan and A. K. Tyagi, Water-dispersible polyphosphate grafted Fe<sub>3</sub>O<sub>4</sub> nanomagnets for cancer therapy, *RSC Adv.*, 2015, **5**, 86754–86762.
- 23 R. Chakravarty, A. Rajeswari, P. Shetty, K. C. Jagadeesan, R. Rama, S. Jadhav, H. D. Sarma, A. Dash and S. Chakraborty, A simple and robust method for radiochemical separation of no-carrier-added <sup>64</sup>Cu produced in a research reactor for radiopharmaceutical preparation, *Appl. Rad. Isot.*, 2020, **165**, 109341.
- 24 S. Chakraborty, K. S. Sharma, A. Rajeswari, K. V. Vimalnath, H. D. Sarma, U. Pandey, J. Jagannath, R. S. Ningthoujam, R. K. Vatsa and A. Dash, Radiolanthanide-loaded agglomerated Fe<sub>3</sub>O<sub>4</sub> nanoparticles for possible use in the treatment of arthritis: formulation, characterization and evaluation in rats, *J. Mater. Chem. B*, 2015, **3**, 5455–5466.
- 25 M. Parsian, G. Unsoy, P. Mutlu, S. Yalcin, A. Tezcaner and U. Gunduz, Loading of gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug, *Eur. J. Pharmacol.*, 2016, **784**, 121–128.
- 26 K. Affram, O. Udofot, A. Cat and E. Agyare, In vitro and in vivo antitumor activity of gemcitabine loaded thermosensitive liposomal nanoparticles and mild hyperthermia in pancreatic cancer, *Int. J. Adv. Res.*, 2015, **3**, 859–874.
- 27 K. O. Affram, T. Smith, E. Ofori, S. Krishnan, P. Underwood, J. G. Trevino and E. Agyare, Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells, *J. Drug Del. Sci. Technol.*, 2020, **55**, 101374.
- 28 E. K. Lim, Y. M. Huh, J. Yang, K. Lee, J. S. Suh and S. Haam, pH-triggered drug releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI, *Adv. Mater.*, 2011, **23**, 2436–2442.
- 29 T. J. Higuchi, Mechanism of sustained-action medication. theoretical analysis of rate of release of solid drugs dispersed in solid matrices, *J. Pharm. Sci.*, 1963, **52**, 1145–1149.
- 30 F. Mottaghitlab, M. Kiani, M. Farokhi, S. C. Kundu, R. L. Reis, M. Gholami, H. Bardania, R. Dinarvand, P. Geramifar, D. Beiki and F. Atyabi, Targeted delivery system based on gemcitabine loaded silk fibroin nanoparticles for lung cancer therapy, *ACS Appl. Mater. Interfaces*, 2017, **9**, 31600–31611.
- 31 A. Pourjavadi, Z. M. Tehrani and A. A. Moghanaki, Folate-conjugated pH-responsive nanocarrier designed for active tumor targeting and controlled release of gemcitabine, *Pharm. Res.*, 2016, **33**, 417–432.
- 32 J.-T. Dai, Y. Zhang, H.-C. Li, Y.-H. Deng, A. A. Elzatahy, A. Alghamdi, D.-L. Fu, Y.-J. Jiang and D.-Y. Zhao, Enhancement of gemcitabine against pancreatic cancer by loading in mesoporous silica vesicles, *Chin. Chem. Lett.*, 2017, **28**, 531–536.
- 33 C. A. Dasanu, Gemcitabine: vascular toxicity and prothrombotic potential, *Expert Opin. Drug Saf.*, 2008, **7**, 703–716.
- 34 N. V. Jadhav, A. I. Prasad, A. Kumar, R. Mishra, S. Dhara, K. R. Babu, C. L. Prajapat, N. L. Misra, R. S. Ningthoujam, B. N. Pandey and R. K. Vatsa, Synthesis of oleic acid functionalized Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles and studying their interaction with tumor cells for potential hyperthermia applications, *Colloids Surf., B*, 2013, **108**, 158–168.
- 35 N. Saxena, H. Agrawal, K. C. Barick, D. Ray, V. K. Aswal, A. Singh, U. C. S. Yadav and C. L. Dube, Thermal and microwave synthesized SPIONs: Energy effects on the efficiency of nano drug carriers, *Mater. Sci. Eng., C*, 2020, **111**, 110792.
- 36 F. Qi, R. Liao, Y. Shuai, H. Pan, G. Qian, S. Peng and C. Shuai, A conductive network enhances nerve cell response, *Addit. Manuf.*, 2022, **52**, 102694.
- 37 C. Shuai, G. Liu, Y. Yang, F. Qi, S. Peng, W. Yang, C. He, G. Wang and G. Qian, A strawberry-like Ag-decorated barium titanate enhances piezoelectric and antibacterial activities of polymer scaffold, *Nano Energy*, 2020, **74**, 104825.
- 38 P. Feng, P. Wu, C. Gao, Y. Yang, W. Guo, W. Yang and C. Shuai, A multimaterial scaffold with tunable properties: toward bone tissue repair, *Adv. Sci.*, 2018, **5**, 1700817.
- 39 N. Vasanth, G. Melchias and P. Kumaravel, Biogenic silver nanoparticles mediated by *Broussonetia papyrifera*: Anti-cancer and antimicrobial activity against pathogenic organisms, *Asian J. Pharm. Clin. Res.*, 2017, **10**, 93–98.
- 40 J. J. Farrell, H. Elsaleh, M. Garcia, R. Lai, A. Ammar, W. F. Regine, R. Abrams, A. B. Benson, J. Macdonald, C. E. Cass, A. P. Dicker and J. R. Mackey, Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer, *Gastroenterology*, 2009, **136**, 187–195.
- 41 S. Singh, K. C. Barick and D. Bahadur, Surface engineered magnetic nanoparticles for removal of toxic metal ions and bacterial pathogens, *J. Hazad. Mater.*, 2011, **192**, 1539–1547.
- 42 H. Xu, L. Cheng, C. Wang, X. Ma, Y. Li and Z. Liu, Polymer encapsulated upconversion nanoparticle/iron oxide nanocomposites for multimodal imaging and magnetic targeted drug delivery, *Biomaterials*, 2011, **32**, 9364–9373.
- 43 F. M. Kievit, Z. R. Stephen, O. Veiseh, H. Arami, T. Wang, V. P. Lai, J. O. Park, R. G. Ellenbogen, M. L. Disis and M. Zhang, Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs, *ACS Nano*, 2012, **6**, 2591–2601.
- 44 J. Huang, L. Bu, J. Xie, K. Chen, Z. Cheng, X. Li and X. Chen, Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles, *ACS Nano*, 2010, **4**, 7151–7160.
- 45 X. H. Peng, X. Qian, H. Mao, A. Y. Wang, Z. G. Chen, S. Nie and D. M. Shin, Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy, *Int. J. Nanomed.*, 2008, **3**, 311–321.

